CytunePharma
Nantes
About CytunePharma
Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer. Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15 Cytune’s proprietary most advanced proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector. Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150. Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $6.7M
- Funding stage: M&A
- Last round: Series Unknown (Jun 2016)
- Website: cytunepharma.com
- Phone: +33 2 40 08 47 23
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cytunepharma-198252 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.